Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry (Q39084538)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 December 2014

Language	Label	Description	Also known as
English	Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry	scientific article published on 5 December 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

quality of life

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

M W M van der Poel

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

S Oerlemans

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

H C Schouten

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

L V van de Poll-Franse

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

5 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

651-661

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Socio-economic implications of cancer survivorship: results from the PROFILES registry

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Personal financial effects of multiple myeloma and its treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2264-0

21 January 2018

Identifiers

10.1007/S00277-014-2264-0

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39084538&oldid=1806938773"